| Paul Eugene Shields, DO | |
|
2501 W 12th St, Suite 1, Erie, PA 16505-4527 | |
| (814) 806-1144 | |
| (814) 833-0659 |
| Full Name | Paul Eugene Shields |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 2501 W 12th St, Erie, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508861949 | NPI | - | NPPES |
| 03446839 | Medicaid | NY | |
| 001370726 | Other | PA | HIGHMARK BCBS |
| 0018397920004 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS010676L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vna Of Western Ny Chha | Williamsville, NY | Home health agency |
| Hospice Buffalo Inc | Cheektowaga, NY | Hospice |
| Kaleida Health | Buffalo, NY | Hospital |
| Elderwood At Wheatfield | Niagara falls, NY | Nursing home |
| Elderwood At Lancaster | Lancaster, NY | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| General Physician Pc | 9537213079 | 333 |
News Archive
The University of Pennsylvania's Basser Research Center for BRCA has announced $6.9 million to research teams both at Penn and at five other institutions across the United States, aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations through multi-disciplinary collaboration.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor - considered key to personalizing cancer treatment - but to map the genetic evolution of disease and monitor response to treatment.
Arcapita, a global investment company, announced today that Atlanta-based CardioMEMS, an Arcapita Ventures portfolio company, has entered into an equity investment and option to purchase agreement with St. Jude Medical, a global medical device company.
Vitamin D has been touted for its beneficial effects on a range of human systems, from enhancing bone health to reducing the risk of developing certain cancers. But it does not improve cholesterol levels, according to a new study conducted at The Rockefeller University Hospital.
› Verified 1 days ago
| Entity Name | General Physician Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093959322 PECOS PAC ID: 9537213079 Enrollment ID: O20090818000154 |
News Archive
The University of Pennsylvania's Basser Research Center for BRCA has announced $6.9 million to research teams both at Penn and at five other institutions across the United States, aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations through multi-disciplinary collaboration.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor - considered key to personalizing cancer treatment - but to map the genetic evolution of disease and monitor response to treatment.
Arcapita, a global investment company, announced today that Atlanta-based CardioMEMS, an Arcapita Ventures portfolio company, has entered into an equity investment and option to purchase agreement with St. Jude Medical, a global medical device company.
Vitamin D has been touted for its beneficial effects on a range of human systems, from enhancing bone health to reducing the risk of developing certain cancers. But it does not improve cholesterol levels, according to a new study conducted at The Rockefeller University Hospital.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul Eugene Shields, DO 397 Churchill Hubbard Rd, Youngstown, OH 44505-1375 Ph: (330) 759-6750 | Paul Eugene Shields, DO 2501 W 12th St, Suite 1, Erie, PA 16505-4527 Ph: (814) 806-1144 |
News Archive
The University of Pennsylvania's Basser Research Center for BRCA has announced $6.9 million to research teams both at Penn and at five other institutions across the United States, aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations through multi-disciplinary collaboration.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor - considered key to personalizing cancer treatment - but to map the genetic evolution of disease and monitor response to treatment.
Arcapita, a global investment company, announced today that Atlanta-based CardioMEMS, an Arcapita Ventures portfolio company, has entered into an equity investment and option to purchase agreement with St. Jude Medical, a global medical device company.
Vitamin D has been touted for its beneficial effects on a range of human systems, from enhancing bone health to reducing the risk of developing certain cancers. But it does not improve cholesterol levels, according to a new study conducted at The Rockefeller University Hospital.
› Verified 1 days ago
Mrs. Marsha Sigrid Dietrich-mclean, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 State St, Erie, PA 16550 Phone: 814-877-4922 Fax: 814-877-3622 | |
Matthew Heitzenrater, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 State St Ste 401, Erie, PA 16507 Phone: 814-877-5333 Fax: 814-877-5329 | |
Dr. Mary Katherine Lasher, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 2501 W 12th St Ste C4, Erie, PA 16505 Phone: 814-461-6626 | |
Matthew Alan Potts, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5515 Peach St, Erie, PA 16509 Phone: 814-864-4031 | |
David Kruszewski, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3125 French St, Erie, PA 16504 Phone: 814-456-2047 | |
Harry Louis Haus, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3823 W 12th St, Erie, PA 16505 Phone: 814-490-3728 | |
Cecilia T. Urquico, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2501 W 12th St, Suite 1, Erie, PA 16505 Phone: 814-806-1144 Fax: 814-833-0659 |